David R. Savello, PhD
Scientific Advisory Board
Dave is currently Senior Vice President of Development at Xenoport, Inc., a biopharmaceutical company focused on therapeutics for central nervous systems disorders. Previously, he served as CEO of NDA Partners, LLC, a drug development consulting company. Prior to this he was Chief Scientific Officer for Cardinal Health, Inc., and before that Senior Vice President for Drug Development at Guilford Pharmaceuticals Inc. He has also held senior level positions in drug development and regulatory affairs with Glaxo Inc. and Glaxo Wellcome Inc., including Vice President for North American Regulatory Affairs. Prior to joining Glaxo, Dave held positions with Warner Lambert Corporation, Boehringer Ingelheim Ltd. and Riker Laboratories. Dave served on the North Carolina State University School of Physical and Mathematical Science Foundation Board and the University of Maryland School of Pharmacy Advisory Committee. He previously served as a director for Panacos Pharmaceuticals (Nasdaq: PANC), a Pappas Ventures portfolio company.